MARY THRONDSON: Open Payments
NPI 1528411196 · CLINTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 50 payments from 12 companies in 2025. Trend: 2023 $538 · 2024 $445 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $325 |
| Axsome Therapeutics, Inc. | 5 | $117 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| ABBVIE INC. | 3 | $49 |
| Novo Nordisk Inc | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| Tris Pharma Inc | 1 | $25 |
| Alkermes, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
Products named: CAPLYTA, Auvelity, Qelbree, REXULTI, VRAYLAR, COBENFY, Dyanavel XR, VIVITROL.
Industry payments across LA — which companies pay providers there.
